Does Lurbinectedin Cause Fetal Abnormalities?
Lurbinectedin (brand name Zepzelca), an alkylating agent for metastatic small cell lung cancer, carries significant risks during pregnancy. It is pregnancy category D, meaning human data or animal studies show fetal risk, but benefits may justify use in life-threatening conditions.[1] Animal reproduction studies reveal embryofetal toxicity: in rats and rabbits, doses at or below human equivalents caused post-implantation loss, decreased fetal weight, and malformations like cleft palate, pointed nose, adactyly (missing digits), flexed limbs, and vertebral/rib anomalies.[2]
No adequate human pregnancy data exist, but the drug's genotoxic mechanism—binding DNA and inhibiting transcription—suggests potential for fetal harm.[3]
FDA Warnings and Labeling
FDA approves lurbinectedin with a boxed warning: it can cause fetal harm. Women of reproductive potential must use effective contraception during treatment and for 6 months after the last dose. Men with female partners of reproductive potential should use contraception during treatment and for 4 months post-dose.[1][2] Embryo-fetal toxicity is explicitly listed, advising pregnancy avoidance.
What Happens in Exposed Pregnancies?
No controlled human trials exist due to ethical concerns. Postmarketing reports are limited, but alkylating agents like lurbinectedin historically link to miscarriage, birth defects, and growth restriction. If exposure occurs, consult maternal-fetal medicine specialists for monitoring, though termination is often recommended.[4]
Contraception and Fertility Impacts
Effective non-hormonal contraception (e.g., IUD, barrier methods) is required, as lurbinectedin may reduce hormonal contraceptive efficacy. It also impairs male and female fertility: animal data show reduced sperm counts and ovarian atrophy.[2] Cryopreservation of sperm/eggs is advised pre-treatment for those planning families.
Safer Alternatives During Pregnancy?
No direct alternatives match lurbinectedin for SCLC, but untreated progression risks maternal death. Topotecan (another category D drug) is sometimes used in pregnancy with monitoring, though still risky. Multidisciplinary input weighs maternal survival against fetal risks.[4]
Regulatory and Clinical Trial Notes
Trials excluded pregnant patients, with no lurbinectedin exposure in fertility studies. Updated labels (e.g., 2023) reinforce warnings based on pharmacology. Report exposures to FDA MedWatch or manufacturer Jazz Pharmaceuticals.[1]
Sources:
[1] [FDA Zepzelca Label (2020, updated)]
[2] [DailyMed Lurbinectedin Label]
[3] [Pharmacology Review (FDA)]
[4] [UpToDate: Chemotherapy in Pregnancy]